News Column

Findings in the Area of Liver Fibrosis Reported from National Research Council CNR (Nanotechnology applications for the therapy of liver fibrosis)

August 13, 2014



By a News Reporter-Staff News Editor at Biotech Week -- Fresh data on Gastroenterology are presented in a new report. According to news reporting from Palermo, Italy, by NewsRx journalists, research stated, "Chronic liver diseases represent a major global health problem both for their high prevalence worldwide and, in the more advanced stages, for the limited available curative treatment options. In fact, when lesions of different etiologies chronically affect the liver, triggering the fibrogenesis mechanisms, damage has already occurred and the progression of fibrosis will have a major clinical impact entailing severe complications, expensive treatments and death in end-stage liver disease."

The news correspondents obtained a quote from the research from National Research Council CNR, "Despite significant advances in the understanding of the mechanisms of liver fibrinogenesis, the drugs used in liver fibrosis treatment still have a limited therapeutic effect. Many drugs showing potent antifibrotic activities in vitro often exhibit only minor effects in vivo because insufficient concentrations accumulate around the target cell and adverse effects result as other non-target cells are affected. Hepatic stellate cells play a critical role in liver fibrogenesis, thus they are the target cells of antifibrotic therapy. The application of nanoparticles has emerged as a rapidly evolving area for the safe delivery of various therapeutic agents (including drugs and nucleic acid) in the treatment of various pathologies, including liver disease."

According to the news reporters, the research concluded: "In this review, we give an overview of the various nanotechnology approaches used in the treatment of liver fibrosis."

For more information on this research see: Nanotechnology applications for the therapy of liver fibrosis. World Journal of Gastroenterology, 2014;20(23):7242-7251. World Journal of Gastroenterology can be contacted at: Baishideng Publishing Group Inc, 8226 Regency Dr, Pleasanton, CA 94588, USA. (Baishideng Publishing Group - www.wjgnet.com/; World Journal of Gastroenterology - www.wjgnet.com/1007-9327/current.htm)

Our news journalists report that additional information may be obtained by contacting L. Giannitrapani, Natl Res Council CNR, Inst Biomed & Mol Immunol A Monroy, I-90146 Palermo, Italy. Additional authors for this research include M. Soresi, M.L. Bondi, G. Montalto and M. Cervello (see also Gastroenterology).

Keywords for this news article include: Italy, Europe, Palermo, Therapy, Liver Fibrosis, Liver Cirrhosis, Gastroenterology

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters